BIIB068
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC50 of 1 nM and a Kd of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research[1].
Product Specifications
CAS Number
[1798787-27-5]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/biib068.html
Concentration
10mM
Purity
99.69
Solubility
DMSO : 31.25 mg/mL (ultrasonic)
Smiles
O=C(N1CC(OC(C)C)C1)NCC2=CC=C(C3=NC(NC4=CN(C)N=C4)=NC=C3)C=C2C
Molecular Formula
C23H29N7O2
Molecular Weight
435.52
Precautions
H302, H315, H319
References & Citations
[1]Bin Ma, Tonika Bohnert, et al. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. J Med Chem. 2020 Jul 22.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15310562 1 Vial
Lentiviral human SLC26A2 shRNA (UAS) - Lentiviral human SLC26A2 shRNA (UAS, RFP) (25)
Ask
View Details MBS6188393-01 0.1 mL
HCK (Hematopoietic Cellular Kinase, p59-HCK/p60-HCK, Tyrosine-protein Kinase HCK, Hemopoietic Cell Kinase) (MaxLight 405)
Ask
View Details MBS6188393-02 5x 0.1 mL
HCK (Hematopoietic Cellular Kinase, p59-HCK/p60-HCK, Tyrosine-protein Kinase HCK, Hemopoietic Cell Kinase) (MaxLight 405)
Ask
View Details 
